STERIS plc
NYSE:STE

Watchlist Manager
STERIS plc Logo
STERIS plc
NYSE:STE
Watchlist
Price: 225 USD -0.6% Market Closed
Market Cap: 22.1B USD

STERIS plc
Investor Relations

Emerging as a silent pioneer in the intricate world of sterilization and infection prevention, STERIS plc has carved out a significant niche in the healthcare industry. Originally founded in 1985, the company has grown through strategic acquisitions and organic expansion. It primarily focuses on protecting patients by ensuring high standards of cleanliness and safety in healthcare environments. STERIS offers a broad array of products and services, from sophisticated sterilization equipment for hospital operating rooms to surface disinfectants and washes that keep healthcare facilities safe and clean. Their diverse portfolio ensures that they can meet the evolving needs of the global healthcare sector, which increasingly demands stringent infection control protocols.

What sets STERIS apart is its innovative approach to both service and product offerings, which blend together to create comprehensive infection prevention solutions. By marrying state-of-the-art technology with a service-oriented business model, the company supports hospitals, medical-device companies, and research labs by maintaining their operational readiness and compliance with health standards. Revenue is generated through a mix of product sales as well as renewable service contracts, which guarantee recurring income. These long-term service agreements, alongside the consistent demand for advanced sterilization solutions, have enabled STERIS to sustain and even enhance its financial health while supporting the mission of safer patient care globally.

Show more
Loading

Earnings Calls

2024 Q4
Feb 6, 2025
Show Transcript
Previous
Next
Yum! Brands Reflects Strong Growth and Strategic Focus for 2025
2024 Q4
Feb 6, 2025

Yum! Brands showcased resilience with a 5% rise in system-wide sales in the fourth quarter, fuelled by robust unit growth. Taco Bell achieved record core profits, contributing to an overall 8% rise in core operating profits for the year. Notably, restaurant margins improved to 17.6%, with expectations for 2025 targeting at least 8% core profit growth. The company anticipates unit growth of 4-5% for 2025, despite recent closures in Turkey. Digital sales surged by 15%, supported by the rollout of their integrated tech platform, Bite, enhancing customer engagement and operational efficiency.

Show Full Analysis

Management

Mr. Daniel A. Carestio
President, CEO & Director
No Bio Available
Mr. Michael J. Tokich
Senior VP & CFO
No Bio Available
Mr. John Adam Zangerle
Senior VP, General Counsel & Secretary
No Bio Available
Ms. Mary Clare Fraser
SVP & Chief Human Resources Officer
No Bio Available
Ms. Karen L. Burton
VP & Chief Accounting Officer
No Bio Available
Ms. Julie Winter
Vice President of Investor Relations & Corporate Communications
No Bio Available
Ms. Julia K. Madsen
Senior VP & GM of Life Sciences
No Bio Available
Mr. Kenneth E. Kohler
Senior VP & GM of AST
No Bio Available
Mr. Walter M. Rosebrough Jr.
CEO Emeritus & Senior Advisor
No Bio Available

Contacts

Address
DUBLIN
Block a Riverside IV, 70 Sir John Rogerson's Quay
Contacts
+35312322000.0
www.steris.com